Global Pharmaceutical Company Merck Acquires Acceleron Pharma for 13 Trillion Won

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Kwon Jae-hee] Global pharmaceutical company Merck is acquiring Acceleron Pharma, a specialist in developing treatments for severe and rare diseases, for $11.5 billion (approximately 13 trillion KRW).

According to the Wall Street Journal (WSJ) on the 30th (local time), Merck valued Acceleron at $180 per share. This deal is considered the largest transaction in Merck's history.

Acceleron is a pharmaceutical company focused on utilizing the transforming growth factor beta (TGF-beta) protein superfamily, which plays a key role in regulating cell growth, differentiation, and recovery processes.

Transforming growth factor beta refers to genes that transform normal cells to promote proliferation.

Rob Davis, CEO of Merck, stated, "The acquisition of Acceleron is a way to strengthen and diversify our broad portfolio."

Following the agreement between the two companies, Merck plans to initiate a tender offer to acquire all outstanding shares of Acceleron through its subsidiary.

Once the acquisition is complete, Merck's subsidiary will merge with Acceleron. The merger is expected to be finalized in the fourth quarter of this year.

This content was produced with the assistance of AI translation services.